Checks whether insulin-making cell channels are lower in type 2 diabetes
Tests one glipizide dose and insulin response in adults with and without diabetes.
Plain-language title generated from the registry record
Registry title: Role of KATP Channel Loss in Type 2 Diabetes
Key facts
- Where
- St Louis, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 65 who are lean, who have obesity with normal blood sugar, who have obesity with impaired fasting glucose, or who have obesity with type 2 diabetes.
- Age
- 18 to 65 years
- Sex
- All sexes can join.
- Disease stage
- Four groups: lean with normal blood sugar (BMI ≥18.5 and <25.0 kg/m²); obesity with normal blood sugar (BMI ≥30 and <50 kg/m²); obesity with impaired fasting glucose (fasting glucose 100-125 mg/dl (5.6–6.9 mmol/L)); obesity with type 2 diabetes (HbA1C 6.5-9.5% (48–80 mmol/mol), fasting glucose ≥126 mg/dl (7 mmol/L), or on diabetes medication).
- Earlier treatment
- People with diabetes must not have changed their diabetes medication in the previous 3 months. Medicines that affect the study results must be stoppable for the study.
- Biomarker or test result
- Fasting plasma glucose, 2-hour oral glucose tolerance test result and HbA1C within the range of the group: for example HbA1C ≤5.6% (38 mmol/mol) in the normal blood sugar groups and 6.5-9.5% in the type 2 diabetes group.
Main reasons for not taking part
- Insulin treatment at more than 0.5 units/kg/day
- Weight change of more than 2% in the last 2 months
- Significant organ disease other than obesity and type 2 diabetes
- Anemia (hemoglobin below 10.0 g/dL)
- Pregnant or breastfeeding
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06830096, who can take part
Where in United States
- Washington University in St. LouisSt Louis, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Washington University School of Medicine
- Trial code
- NCT06830096
- Record updated
- 10 August 2026
- Original description
Insulin is a hormone that is made by β-cells in the pancreas and when released into the bloodstream helps control blood sugar levels. Insulin release is regulated by electrical activity in the β-cell which is generated by the ATP-sensitive potassium (KATP) channel. While reduced KATP activity is associated with increased insulin secretion, animals lacking KATP exhibit reduced secretion. This crossover from hypersecretion to undersecretion with KATP loss mirrors insulin secretion during type 2 diabetes. Intriguingly, evidence from cell and animal models suggest that chronically stimulated β-cells can lose KATP revealing a possible role for KATP loss in the failure of insulin secretion and poor control of blood sugar observed in type 2 diabetes. This study will therefore examine insulin responses following ingestion of a single dose of a sulfonylurea called glipizide that inhibits KATP channels in people with and without type 2 diabetes. The goal is to determine whether KATP channel activity is reduced during type 2 diabetes progression.Read full original descriptionShow less
Hyperglycemia Induced Hyperexcitability: A Novel Role for KATP in the Progression of Type 2 Diabetes
Insulin is a hormone that is made by β-cells in the pancreas and when released into the bloodstream helps control blood sugar levels. Insulin release is regulated by electrical activity in the β-cell which is generated by the ATP-sensitive potassium (KATP) channel. While reduced KATP activity is associated with increased insulin secretion, animals lacking KATP exhibit reduced secretion. This crossover from hypersecretion to undersecretion with KATP loss mirrors insulin secretion during type 2 diabetes. Intriguingly, evidence from cell and animal models suggest that chronically stimulated β-cells can lose KATP revealing a possible role for KATP loss in the failure of insulin secretion and poor control of blood sugar observed in type 2 diabetes. This study will therefore examine insulin responses following ingestion of a single dose of a sulfonylurea called glipizide that inhibits KATP channels in people with and without type 2 diabetes. The goal is to determine whether KATP channel activity is reduced during type 2 diabetes progression.
Inclusion: Lean-normoglycemic group (n=10): BMI ≥18.5 and <25.0 kg/m², fasting plasma glucose concentration <95 mg/dl, 2-hr oral glucose tolerance test plasma glucose concentration ≤140-mg/dl, and hemoglobin A1C (HbA1C) ≤5.6%; Obesity-normoglycemic group (n=10): BMI ≥30 and <50 kg/m², fasting plasma glucose concentration <95 mg/dl, 2-hr oral glucose tolerance test plasma glucose concentration ≤140 mg/dl, and hemoglobin A1C (HbA1C) ≤5.6%; Obesity-impaired fasting glucose group (n=10): BMI ≥30 and <50 kg/m², fasting plasma glucose concentration 100-125 mg/dl, and 2-hr oral glucose tolerance test plasma glucose concentration <200 mg/dl; Obesity-type 2 diabetes group (n=10): BMI ≥30 and <50 kg/m²; HbA1C 6.5-9.5%, fasting plasma glucose ≥126 mg/dl, 2-hr oral glucose tolerance test plasma glucose concentration ≥200 mg/dl and/or medical history of T2DM and currently using anti-diabetic medications.
Exclusion: Any change in diabetes medication in previous 3 months; Unstable weight (>2% change during the last 2 months before entering the study); Use of medications that are known to affect the study outcome measures (e.g., steroids, non-statin lipid-lowering medications) or increase the risk of study procedures (e.g., anticoagulants) and that cannot be temporarily discontinued for this study; Unable or unwilling to follow the study protocol or for any reason the research team believes the volunteer is not an appropriate candidate for this study, including non-compliance with screening appointments or previous medical visits; Diabetes therapy with insulin at >0.5 units/kg/day; Evidence of significant organ system dysfunction or disease other than obesity and T2D; Anemia (Hemoglobin <10.0 g/dL); Regular use of tobacco products; Excessive consumption of alcohol (≥3 drinks/day for men and ≥2 drinks/day for women); Pregnant or breastfeeding.